RxDoctor Payments Data

Corin Newman, NP

Nurse Practitioner · Miller Place, NYNPI 1801482062

Payments from drug & device makers

$1,701in general payments, 2019–2025

Across 51 payments — averaging $33.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$408
  • Amgen$190
  • Bayer$150
  • AstraZeneca$150
  • Relievant Medsystems, Inc.$141
  • Harmony Biosciences LLC$125
  • plus $537 from 12 others

What the payments were for

  • Food & beverage$1,701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,701 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$57,414
Medicare patients
126
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$44,150
OzempicSemaglutide17$22,549
MounjaroTirzepatide21$21,491
EliquisApixaban14$12,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,547
Atorvastatin Calcium182$1,495
Metoprolol Succinate120$1,242
Rosuvastatin Calcium68$1,097
Tramadol Hcl22$984
Ezetimibe44$969
Albuterol Sulfate HfaAlbuterol Sulfate38$928
Gabapentin51$876
Duloxetine Hcl19$875
Mirtazapine23$639
Levothyroxine Sodium69$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$408$44,15034 claims
Novo NordiskOzempic$77$22,54917 claims
Lilly USA, LLCMounjaro$93$21,49121 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$63369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Miller Place

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →